InvestorsHub Logo
Followers 21
Posts 635
Boards Moderated 0
Alias Born 11/08/2018

Re: Bouf post# 278287

Saturday, 06/06/2020 2:53:27 AM

Saturday, June 06, 2020 2:53:27 AM

Post# of 425937
The Du trial -why oh why Amarin did not get for the Du trial a detailed statistical re analysis undertaken and presented in evidence as needs be of the few studies that generics were relying upon .????.. what would it have cost ? We should reflect that Mori was a very old study on 59 men over a period of 6 weeks - not much by way of resource was ever devoted to the original Mori study so they should have been looking for the holes in it with a microscope
Surely every word / statistic on the Mori paper should have been critically examined given the substantial reliance generics were placing on it - same goes for the K study and anything else generics relies upon
As a lawyer I consider - if it is an incontrovertible fact that the Mori study contains statistical error on the face of the paper then the FC must admit that into its appeal -it maybe be that Singer will invite the generics to concede such incontrovertible statistical error into the appeal - it places generics in an invidious position - relying on statistics from an old study where the statistical analysis was error
It would be against the basic principles of jurisprudence to allow an outcome in litigation to remain if it is based on a fact (facts) which are -subsequent to an original finding-clearly demonstrates and indisputably shown to be incorrect
This circumstance adds great further weight to the strength of this appeal
Alm
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News